This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNeptune Wellness Solutions（NTU）株式概要ネプチューン・ウェルネス・ソリューションズ社は、カナダ、米国、および国際的に消費者向けパッケージ商品会社として事業を展開している。 詳細NTU ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析過去5年間で収益は年間13.6%減少しました。 意味のある時価総額がありません ( €106K )マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ +2 さらなるリスクすべてのリスクチェックを見るNTU Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.1198.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-112m98m2016201920222025202620282031Revenue US$98.4mEarnings US$9.5mAdvancedSet Fair ValueView all narrativesNeptune Wellness Solutions Inc. 競合他社NosiumSymbol: NGM:NOSIUM BMarket cap: SEK 9.3mBruush Oral CareSymbol: OTCPK:BRSH.FMarket cap: US$14.4kKoios BeverageSymbol: CNSX:FITMarket cap: CA$473.6kHillSymbol: TSXV:HILL.HMarket cap: CA$36.1k価格と性能株価の高値、安値、推移の概要Neptune Wellness Solutions過去の株価現在の株価US$0.1152週高値US$12.3252週安値US$0.04ベータ2.181ヶ月の変化0%3ヶ月変化-10.66%1年変化-97.90%3年間の変化-99.99%5年間の変化-100.00%IPOからの変化-100.00%最新ニュースお知らせ • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.お知らせ • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removedお知らせ • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.お知らせ • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.最新情報をもっと見るRecent updatesお知らせ • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.お知らせ • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removedお知らせ • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.お知らせ • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.お知らせ • Oct 14Neptune Wellness Solutions Inc. Announces Completed Settlement of Class Action LawsuitNeptune Wellness Solutions Inc. has completed the previously announced settlement of a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors.お知らせ • Aug 17Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 08/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 05Neptune Wellness Solutions Inc. Announces CFO ChangesNeptune Wellness Solutions Inc. announced the promotion of Lisa Gainsborg, currently Neptune's Financial Controller, to Interim Chief Financial Officer, effective immediately, replacing Raymond Silcock who has resigned for personal reasons. Ms. Gainsborg possesses significant experience and knowledge of accounting and finance across both public and private companies, with background in financial statement preparation, Securities and Exchange Commission reporting, Sarbanes-Oxley compliance, the creation of accounting and reporting controls and procedures, and experience with developing enterprise resource planning systems. Ms. Gainsborg previously held financial leadership roles at several companies including Basanite Inc., Zero Gravity Solutions Inc., A+ Accounting Services Inc. She has also provided chief financial officer consulting services and accounting system support for clients and prepared corporate, partnership, and individual tax returns. Ms. Gainsborg is a Certified Public Accountant in Florida and Maryland. She received a Bachelor of Business Administration in Accounting from Hofstra University in 1989.お知らせ • Jul 01Neptune Wellness Solutions Inc. announced delayed annual 10-K filingOn 06/30/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 17Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 12,121,212 Price\Range: $0.33 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 12,121,212お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 07Neptune Wellness Solutions Announces Receipt of NASDAQ NotificationNeptune Wellness Solutions Inc. announced that the Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for the Company's common shares listed on Nasdaq be maintained at a minimum of $1.00. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from November 15, 2022 to December 28, 2022, the Company no longer met the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Company's common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 27, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's common shares will continue to trade on the Nasdaq Capital Market. To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. In the event the Company does not regain compliance by June 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.お知らせ • Nov 23Neptune Wellness Solutions Inc. Revises Revenue Guidance for the Second Quarter of Fiscal Year 2023Neptune Wellness Solutions Inc. revised revenue guidance for the second quarter of fiscal year 2023. For the period, the company expects revenue range from USD 12.5 million to USD 13.5 million to USD 11.5 million to USD 12.5 million. Approximately 70% of second quarter revenues were from Sprout, representing a double digit increase compared to the same quarter last year.お知らせ • Nov 16+ 1 more updateNeptune Wellness Solutions Inc. announced delayed 10-Q filingOn 11/15/2022, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 10PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc. PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million on November 9, 2022.お知らせ • Oct 22Neptune Wellness Solutions Inc. Reaches Settlement in Shareholder Class Action LitigationNeptune Wellness Solutions Inc. announced that it has agreed to settle and resolve a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors, captioned Gong v. Neptune Wellness Solutions Inc. (Case No. 2:21-cv-01386-ENV-ARL) pending in the United States District Court for the Eastern District of New York (the "Court"). The litigation relates to allegations that, among other things, the Company had made misrepresentations of material information. The settlement provides for a gross payment to the class of between $4 and $4.25 million, with the exact amount being within the Company's control and dependent on the type of consideration used. The settlement is subject to Court approval and certification by the Court of the class. The settlement will resolve this matter against all defendants, and the consideration will be used to satisfy settlement administrator expenses, plaintiffs' attorneys' fees and costs, and payments to all members of the Class. In exchange for the settlement consideration, the Company and the other defendants will be released from all claims by the plaintiffs and the class. The Company denies all wrongdoing and liability and the settlement does not constitute an admission of wrongdoing or liability by the Company or any defendant. The class is comprised of all persons and entities that purchased or otherwise acquired Neptune securities on the NASDAQ or another U.S. trading venue between July 24, 2019, and July 15, 2021. The settlement is contingent upon various conditions, including, but not limited to, preliminary approval by the Court and final approval by the Court after notice to the class, certification of the class and a hearing. There can be no assurance that the settlement will be approved by the Court nor upheld if challenged on appeal. In addition, the Company has the right to terminate the settlement agreement under certain conditions. The Company has filed a claim for coverage with its insurance carrier, which was subsequently denied. The Company is contesting the denial of coverage.お知らせ • Oct 19PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc.お知らせ • Oct 13Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offeringお知らせ • Oct 12+ 1 more updateNeptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct OfferingBoard Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 6 highly experienced directors. Independent Director Ronald Denis is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Mar 03President recently bought €346k worth of stockOn the 1st of March, Michael Cammarata bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €365k worth in shares.Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: CA$0.11 loss per share (up from CA$0.59 loss in 3Q 2021). Revenue: CA$18.4m (up 456% from 3Q 2021). Net loss: CA$18.7m (loss narrowed 75% from 3Q 2021). Revenue exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 81%, compared to a 6.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 16Second quarter 2022 earnings released: CA$0.076 loss per share (vs CA$0.20 loss in 2Q 2021)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2022 results: Revenue: CA$15.7m (down 45% from 2Q 2021). Net loss: CA$12.7m (loss narrowed 42% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.Board Change • Sep 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Executive Departure • Sep 01Independent Director Jane Pemberton has left the companyOn the 26th of August, Jane Pemberton's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Jane still personally held only 9.67k shares (€9.2k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Sep 01Independent Director Frank Rochon has left the companyOn the 26th of August, Frank Rochon's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Frank still personally held only 4.77k shares (€4.6k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Recent Insider Transactions • Jul 22Independent Chairman recently bought €67k worth of stockOn the 20th of July, John Moretz bought around 100k shares on-market at roughly €0.67 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €210k worth in shares.Reported Earnings • Jul 18Full year 2021 earnings released: CA$1.38 loss per share (vs CA$0.68 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$46.8m (up 58% from FY 2020). Net loss: CA$167.1m (loss widened 175% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.Executive Departure • May 23Independent Director has left the companyOn the 17th of May, Richard Schottenfeld's tenure as Independent Director ended after 4.9 years in the role. As of March 2021, Richard personally held 180.45k shares (€182k worth at the time). A total of 3 executives have left over the last 12 months.Is New 90 Day High Low • Mar 06New 90-day low: €1.15The company is down 18% from its price of €1.40 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.Reported Earnings • Feb 18Third quarter 2021 earnings released: CA$0.59 loss per share (vs CA$0.06 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CA$3.32m (down 64% from 3Q 2020). Net loss: CA$73.8m (down CA$79.4m from profit in 3Q 2020).Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 78%. Over the next year, revenue is forecast to grow 183%, compared to a 5.4% growth forecast for the Personal Products industry in Germany.Is New 90 Day High Low • Feb 06New 90-day high: €1.93The company is up 5.0% from its price of €1.83 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 5.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day low: €1.17The company is down 41% from its price of €1.97 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions • Nov 22Independent Chairman recently bought €143k worth of stockOn the 19th of November, John Moretz bought around 100k shares on-market at roughly €1.43 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.株主還元NTUDE Personal ProductsDE 市場7D0%4.3%1.6%1Y-97.9%-6.7%2.2%株主還元を見る業界別リターン: NTU過去 1 年間で-6.7 % の収益を上げたGerman Personal Products業界を下回りました。リターン対市場: NTUは、過去 1 年間で2.2 % のリターンを上げたGerman市場を下回りました。価格変動Is NTU's price volatile compared to industry and market?NTU volatilityNTU Average Weekly Movementn/aPersonal Products Industry Average Movement5.2%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: NTUの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNTUのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199850Mike de Geuswww.neptunecorp.comネプチューン・ウェルネス・ソリューションズ社は、カナダ、米国、および国際的に消費者向けパッケージ商品会社として事業を展開している。同社の製品ポートフォリオには、オメガ3系フィッシュオイルやその他の栄養製品、Biodrogaブランドのソフトジェル・ソリューションが含まれ、オメガ3系脂肪酸を事前に消化する酵素を使用したオメガ3系脂肪酸デリバリー技術であるMaxSimilを提供している。フォレスト・レメディーズのブランドでビーガンマルチオメガグミとソフトジェル、スプラウトのブランドでオーガニックベビーフード製品を提供している。代理店、小売店、食料品店、オンラインではforestremedies.com、sproutorganics.com、eコマースサイトを通じて製品を提供している。ネプチューン・ウェルネス・ソリューションズ社は1998年に法人化され、カナダのラバルに本社を置いている。もっと見るNeptune Wellness Solutions Inc. 基礎のまとめNeptune Wellness Solutions の収益と売上を時価総額と比較するとどうか。NTU 基礎統計学時価総額€105.51k収益（TTM）-€49.84m売上高(TTM)€36.43m0.0xP/Sレシオ0.0xPER（株価収益率NTU は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NTU 損益計算書（TTM）収益US$39.11m売上原価US$39.87m売上総利益-US$758.79kその他の費用US$52.76m収益-US$53.52m直近の収益報告Dec 31, 2023次回決算日該当なし一株当たり利益（EPS）-10.86グロス・マージン-1.94%純利益率-136.83%有利子負債／自己資本比率-49.8%NTU の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/06/12 04:22終値2024/03/15 00:00収益2023/12/31年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neptune Wellness Solutions Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Aaron GreyAlliance Global PartnersDouglas LoeCantor Fitzgerald Canada CorporationJason ButlerCitizens JMP Securities, LLC7 その他のアナリストを表示
お知らせ • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.
お知らせ • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed
お知らせ • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024
お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.
お知らせ • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
お知らせ • Mar 09+ 1 more updateNeptune Wellness Solutions Inc. Appoints Michael De Geus as Interim President and Cedrick Billequey as Interim COONeptune Wellness Solutions Inc. announced the Company's Board of Directors has named Board member Michael De Geus Interim President, effective March 8, 2024. Mr. De Geus has served as an integral member of the previously disclosed Restructuring Committee of the Board of Directors following the furlough and departure of Michael Cammarata, who served as President and Chief Executive Officer since 2019. Additionally, the Company's Board of Directors has named Cedrick Billequey, currently General Manager of Neptune's subsidiary Biodroga Nutraceuticals Inc. ("Biodroga"), Interim Chief Operating Officer of Neptune. He will continue his role at Biodroga concurrently with his interim appointment. Mr. De Geus has been a director of Neptune since April 2020. He is a highly accomplished security executive with almost 20 years of domestic and international safety, protection and entrepreneurship experience. His 12-year career with the United States Secret Service afforded him the opportunity to become an expert in the art of protection and problem solving where he focused on safeguarding people, places and things all over the world. He is experienced in leading Presidential details for multiple US Presidents, leading cyber security, fraud, and financial crimes investigations, including the largest data breach cases in US Secret Service history, and operationalizing large mission-based teams. He is also the founder of Leatherback Gear (the only patented personal protection system D2C) and HERO Beverage Co. (with the goal of Helping Everyone Remain Operational, benefiting first responders, servicemen and women, and other heroes). He holds a Bachelor of Sciences in Criminal Justice from California State University, Fullerton, a Master of Sciences in International Relations from Troy State University, and was a PhD Candidate in Public Policy specializing in Homeland Security. Mr. Billequey has been leading Biodroga, Neptune's nutraceuticals brand subsidiary, for over three years, during which time Biodroga expanded its client portfolio and became a profitable company. He led the restructuring of the entire Biodroga team and its processes to ensure superior customer service levels and scalability. Cedrick possesses significant experience and knowledge in B2B business development and supply chain optimization, with a solid background in finance. Prior to joining Biodroga, Cedrick worked over 20 years in the Pharmaceutical industry where he held various leadership roles in International Business Development, Supply Chain, Project Management and Finance. He worked many years at Pharmascience, one of the largest generic pharmaceutical companies in Canada, before joining Jamp Pharma Corporation as Vice-President International Business Development, one of the fastest growing Canadian Pharmaceutical companies. In 1999, he received a Bachelor of Business Administration in Finance from the University of Alabama in Huntsville.
お知らせ • Mar 07+ 1 more updateNeptune Wellness Solutions Inc.(OTCPK:NEPT.F) dropped from NASDAQ Composite IndexNeptune Wellness Solutions Inc removed
お知らせ • Feb 17Neptune Wellness Solutions Inc. to Report Q3, 2024 Results on Feb 16, 2024Neptune Wellness Solutions Inc. announced that they will report Q3, 2024 results on Feb 16, 2024
お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2024, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 05Neptune Wellness Announces Receipt of Nasdaq Delisting Notice and Intention to AppealNeptune Wellness Solutions Inc. (‘Neptune’ or the ‘Company’) announced that it received notification from the Nasdaq Stock Market LLC (‘Nasdaq’) on November 30, 2023, that Nasdaq has determined to delist the Company's common shares (the ‘Common Shares’) due to noncompliance with the Minimum Bid Requirement and the Stockholders’ Equity Requirement (each as defined below). The notification specifies that the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market (NASDAQ Listing Rule 5550(a)(2)), as the bid price for the Common Shares on Nasdaq closed below USD 1.00 (the ‘Minimum Bid Requirement’) for 30 consecutive trading days. As the Company previously implemented two reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, it is not eligible for any compliance period specified in Rule 5810(c)(3)(A). In addition, as previously disclosed, the Company received notification on July 19, 2023, that it was not in compliance with the minimum stockholders’ equity requirement (NASDAQ Listing Rule 5550(b)(1)), as the Company's stockholders’ equity was below the minimum USD 2.5 million required (the ‘Stockholders’ Equity Requirement’). The Company was provided 180 calendar days, or until January 16, 2024, to regain compliance with the Stockholders’ Equity Requirement. This deficiency serves as an additional and separate basis for delisting. The Company intends to appeal the determination made by Nasdaq within seven calendar days, or by December 7, 2023, pursuant to the procedures set forth in the Nasdaq Listing Rules. The Nasdaq Listing Rules provide that the Company may request a hearing before a Nasdaq Hearings Panel (the ‘Panel’), and such hearing request will stay the suspension of the Company's securities pending the Panel's decision. There can be no assurance as to the success or outcome of the appeal.
お知らせ • Nov 21Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. approximately $110 million.Neptune Wellness Solutions Inc. (NasdaqCM:NEPT) entered into a non-binding Letter of Intent to acquire Datasys Group Inc. for approximately $110 million on November 20, 2023. Total potential consideration for the acquisition is $112 million in a combination of $20 million in cash at closing, $32 million in restricted equity based on a pre-closing VWAP of the Company’s share price on NASDAQ (subject to a minimum of 10 million shares) and restricted until three gradual releases over 10-30 months, a 5-year $31 million PIK seller note. An earnout payment ranging from $5 million to $22 million, subject to Datasys achieving 2024 EBITDA thresholds between $13 million and $16 million. The Proposed Transaction is subject to the negotiation of definitive documentation between the parties and it is anticipated that closing of the Proposed Transaction would be subject to shareholder approval and additional terms and conditions, including the need for the Company to secure financing for the cash portion of the consideration and satisfactory due diligence by the respective parties. There can be no assurance that a definitive agreement will be entered into or that the Proposed Transaction will be consummated on the terms or timeframe currently contemplated, or at all.
お知らせ • Oct 14Neptune Wellness Solutions Inc. Announces Completed Settlement of Class Action LawsuitNeptune Wellness Solutions Inc. has completed the previously announced settlement of a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors.
お知らせ • Aug 17Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 08/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 05Neptune Wellness Solutions Inc. Announces CFO ChangesNeptune Wellness Solutions Inc. announced the promotion of Lisa Gainsborg, currently Neptune's Financial Controller, to Interim Chief Financial Officer, effective immediately, replacing Raymond Silcock who has resigned for personal reasons. Ms. Gainsborg possesses significant experience and knowledge of accounting and finance across both public and private companies, with background in financial statement preparation, Securities and Exchange Commission reporting, Sarbanes-Oxley compliance, the creation of accounting and reporting controls and procedures, and experience with developing enterprise resource planning systems. Ms. Gainsborg previously held financial leadership roles at several companies including Basanite Inc., Zero Gravity Solutions Inc., A+ Accounting Services Inc. She has also provided chief financial officer consulting services and accounting system support for clients and prepared corporate, partnership, and individual tax returns. Ms. Gainsborg is a Certified Public Accountant in Florida and Maryland. She received a Bachelor of Business Administration in Accounting from Hofstra University in 1989.
お知らせ • Jul 01Neptune Wellness Solutions Inc. announced delayed annual 10-K filingOn 06/30/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 17Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $4 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 12,121,212 Price\Range: $0.33 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 12,121,212
お知らせ • Feb 16Neptune Wellness Solutions Inc. announced delayed 10-Q filingOn 02/15/2023, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 07Neptune Wellness Solutions Announces Receipt of NASDAQ NotificationNeptune Wellness Solutions Inc. announced that the Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on December 29, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for the Company's common shares listed on Nasdaq be maintained at a minimum of $1.00. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from November 15, 2022 to December 28, 2022, the Company no longer met the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Company's common shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until June 27, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's common shares will continue to trade on the Nasdaq Capital Market. To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive trading days. In the event the Company does not regain compliance by June 27, 2023, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its common shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding common shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
お知らせ • Nov 23Neptune Wellness Solutions Inc. Revises Revenue Guidance for the Second Quarter of Fiscal Year 2023Neptune Wellness Solutions Inc. revised revenue guidance for the second quarter of fiscal year 2023. For the period, the company expects revenue range from USD 12.5 million to USD 13.5 million to USD 11.5 million to USD 12.5 million. Approximately 70% of second quarter revenues were from Sprout, representing a double digit increase compared to the same quarter last year.
お知らせ • Nov 16+ 1 more updateNeptune Wellness Solutions Inc. announced delayed 10-Q filingOn 11/15/2022, Neptune Wellness Solutions Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 10PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc. PurCann Pharma Inc. completed the acquisition of Cannabis Assets of Neptune Wellness Solutions Inc. for CAD 5.2 million on November 9, 2022.
お知らせ • Oct 22Neptune Wellness Solutions Inc. Reaches Settlement in Shareholder Class Action LitigationNeptune Wellness Solutions Inc. announced that it has agreed to settle and resolve a putative shareholder class action lawsuit filed against Neptune and certain of its current and former officers and directors, captioned Gong v. Neptune Wellness Solutions Inc. (Case No. 2:21-cv-01386-ENV-ARL) pending in the United States District Court for the Eastern District of New York (the "Court"). The litigation relates to allegations that, among other things, the Company had made misrepresentations of material information. The settlement provides for a gross payment to the class of between $4 and $4.25 million, with the exact amount being within the Company's control and dependent on the type of consideration used. The settlement is subject to Court approval and certification by the Court of the class. The settlement will resolve this matter against all defendants, and the consideration will be used to satisfy settlement administrator expenses, plaintiffs' attorneys' fees and costs, and payments to all members of the Class. In exchange for the settlement consideration, the Company and the other defendants will be released from all claims by the plaintiffs and the class. The Company denies all wrongdoing and liability and the settlement does not constitute an admission of wrongdoing or liability by the Company or any defendant. The class is comprised of all persons and entities that purchased or otherwise acquired Neptune securities on the NASDAQ or another U.S. trading venue between July 24, 2019, and July 15, 2021. The settlement is contingent upon various conditions, including, but not limited to, preliminary approval by the Court and final approval by the Court after notice to the class, certification of the class and a hearing. There can be no assurance that the settlement will be approved by the Court nor upheld if challenged on appeal. In addition, the Company has the right to terminate the settlement agreement under certain conditions. The Company has filed a claim for coverage with its insurance carrier, which was subsequently denied. The Company is contesting the denial of coverage.
お知らせ • Oct 19PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million.PurCann Pharma Inc. entered into a binding agreement to acquire Cannabis Assets of Neptune Wellness Solutions Inc. for approximately CAD 6 million on October 16, 2022. The cannabis assets include includes the cannabis plant in Sherbrooke, Québec, the Mood Ring and PanHash brands, and related assets. Neptune intends to use the net proceeds from the sale of these assets to for working capital and other general corporate purposes. The Transaction is expected to close on or before November 15, 2022. Stifel Nicolaus Canada Inc. acted as financial opinion provider and exclusive financial advisor to Neptune Wellness Solutions Inc. Osler, Hoskin & Harcourt LLP acted as legal advisor to Neptune Wellness Solutions Inc.
お知らせ • Oct 13Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offering
お知らせ • Oct 12+ 1 more updateNeptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million.Neptune Wellness Solutions Inc. has completed a Follow-on Equity Offering in the amount of $6.000002 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 3,208,557 Price\Range: $1.87 Discount Per Security: $0.0748 Transaction Features: Registered Direct Offering
Board Change • Jun 02High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 6 highly experienced directors. Independent Director Ronald Denis is the most experienced director on the board, commencing their role in 2000. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Mar 03President recently bought €346k worth of stockOn the 1st of March, Michael Cammarata bought around 1m shares on-market at roughly €0.31 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of €365k worth in shares.
Reported Earnings • Feb 11Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: CA$0.11 loss per share (up from CA$0.59 loss in 3Q 2021). Revenue: CA$18.4m (up 456% from 3Q 2021). Net loss: CA$18.7m (loss narrowed 75% from 3Q 2021). Revenue exceeded analyst estimates by 6.1%. Over the next year, revenue is forecast to grow 81%, compared to a 6.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 16Second quarter 2022 earnings released: CA$0.076 loss per share (vs CA$0.20 loss in 2Q 2021)The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2022 results: Revenue: CA$15.7m (down 45% from 2Q 2021). Net loss: CA$12.7m (loss narrowed 42% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 47% per year, which means it has not declined as severely as earnings.
Board Change • Sep 13High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 05High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Jane Pemberton was the last director to join the board, commencing their role in 2020. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Executive Departure • Sep 01Independent Director Jane Pemberton has left the companyOn the 26th of August, Jane Pemberton's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Jane still personally held only 9.67k shares (€9.2k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Sep 01Independent Director Frank Rochon has left the companyOn the 26th of August, Frank Rochon's tenure as Independent Director ended after 1.0 years in the role. As of June 2021, Frank still personally held only 4.77k shares (€4.6k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Recent Insider Transactions • Jul 22Independent Chairman recently bought €67k worth of stockOn the 20th of July, John Moretz bought around 100k shares on-market at roughly €0.67 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €210k worth in shares.
Reported Earnings • Jul 18Full year 2021 earnings released: CA$1.38 loss per share (vs CA$0.68 loss in FY 2020)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: CA$46.8m (up 58% from FY 2020). Net loss: CA$167.1m (loss widened 175% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
Executive Departure • May 23Independent Director has left the companyOn the 17th of May, Richard Schottenfeld's tenure as Independent Director ended after 4.9 years in the role. As of March 2021, Richard personally held 180.45k shares (€182k worth at the time). A total of 3 executives have left over the last 12 months.
Is New 90 Day High Low • Mar 06New 90-day low: €1.15The company is down 18% from its price of €1.40 on 04 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 4.0% over the same period.
Reported Earnings • Feb 18Third quarter 2021 earnings released: CA$0.59 loss per share (vs CA$0.06 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CA$3.32m (down 64% from 3Q 2020). Net loss: CA$73.8m (down CA$79.4m from profit in 3Q 2020).
Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 78%. Over the next year, revenue is forecast to grow 183%, compared to a 5.4% growth forecast for the Personal Products industry in Germany.
Is New 90 Day High Low • Feb 06New 90-day high: €1.93The company is up 5.0% from its price of €1.83 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day low: €1.17The company is down 41% from its price of €1.97 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions • Nov 22Independent Chairman recently bought €143k worth of stockOn the 19th of November, John Moretz bought around 100k shares on-market at roughly €1.43 per share. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares.
